BCR-ABL inhibitor HS-10382

An orally bioavailable, allosteric tyrosine kinase inhibitor of the BCR-ABL fusion oncoprotein, with potential antineoplastic activity. Upon oral administration, BCR-ABL inhibitor HS-10382 targets and binds to the ABL myristoyl pocket, locking BCR-ABL into an inactive conformation, thereby inhibiting the activity of BCR-ABL and decreasing the proliferation of tumor cells. BCR-ABL fusion protein is an aberrantly activated tyrosine kinase produced by certain leukemia cells.